Home › Bile Duct Cancer (Cholangiocarcinoma) › Pennsylvania › Philadelphia
Bile Duct Cancer (Cholangiocarcinoma) clinical trials in Philadelphia, PA
5 studies for Bile Duct Cancer (Cholangiocarcinoma) are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
TCR1188-ABC Cells in KRAS-mutated Cancers
RecruitingPhase 1
- University of Pennsylvania, Philadelphia
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Thomas Jefferson University, Philadelphia
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
RecruitingPhase 1
- Sidney Kimmel Cancer Center, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Philadelphia
Bile Duct Cancer (Cholangiocarcinoma) trials in other cities
- Houston, TX13 studies
- New York City, NY11 studies
- Boston, MA8 studies
- Rochester, MN7 studies
- Arlington, VA7 studies
- Los Angeles, CA7 studies
- Chicago, IL7 studies
- Columbus, OH6 studies
- Cleveland, OH6 studies
- Queens, NY5 studies
- Edison, NJ5 studies
- Grand Rapids, MI5 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.